Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients

A double-blind, randomized, controlled clinical study

Giuseppe Barbaro, Giorgio Barbarini, Gabriella Di Lorenzo

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The aim of this study was to assess the role and the therapeutic efficacy of 2 azole antifungal drugs, fluconazole and itraconazole, in the treatment of endoscopically diagnosed Candida esophagitis in patients with acquired immunodeficiency syndrome (AIDS). The study involved 123 human immunodeficiency virus (HIV)-positive patients (70 males and 53 females, mean age 27 years) at their first episode of esophageal candidiasis diagnosed by endoscopy. The patients were randomized in a double-blind design to receive either fluconazole (100 mb b.i.d. per os) or itraconazole (100mg b.i.d. per os). In order to evaluate the efficacy of treatment, clinical examinations were performed every week up to the end of follow-up (2 months); endoscopic examination was performed at baseline, at the end of treatment (3 weeks) and at the end of follow-up. At the end of the treatment, cure, as judged by endoscopy, was observed in 74% of fluconazole-treated patients and in 47.2% of itraconazole-treated patients (p <0.01); at the end of follow-up, cure was observed endoscopically in 71.7% of fluconazole-treated patients and in 43.2% of the itraconazole-treated patients (p <0.05). As regards clinical cure, no statistically significant difference was observed between the groups, at the end of pharmacological treatment and at the end of follow-up. The results of this study demonstrate that both fluconazole and itraconazole are efficacious in the treatment of Candida esophagitis in AIDS patients; fluconazole is associated with higher rate of endoscopic cure than is itraconazole.

Original languageEnglish
Pages (from-to)613-617
Number of pages5
JournalScandinavian Journal of Infectious Diseases
Volume27
Issue number6
DOIs
Publication statusPublished - 1995

Fingerprint

Itraconazole
Fluconazole
Candidiasis
Acquired Immunodeficiency Syndrome
Esophagitis
Therapeutics
Candida
Endoscopy
Azoles
Clinical Studies
HIV
Pharmacology

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Immunology

Cite this

@article{8b49d416674d42b79fb1870ebb2c0b77,
title = "Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: A double-blind, randomized, controlled clinical study",
abstract = "The aim of this study was to assess the role and the therapeutic efficacy of 2 azole antifungal drugs, fluconazole and itraconazole, in the treatment of endoscopically diagnosed Candida esophagitis in patients with acquired immunodeficiency syndrome (AIDS). The study involved 123 human immunodeficiency virus (HIV)-positive patients (70 males and 53 females, mean age 27 years) at their first episode of esophageal candidiasis diagnosed by endoscopy. The patients were randomized in a double-blind design to receive either fluconazole (100 mb b.i.d. per os) or itraconazole (100mg b.i.d. per os). In order to evaluate the efficacy of treatment, clinical examinations were performed every week up to the end of follow-up (2 months); endoscopic examination was performed at baseline, at the end of treatment (3 weeks) and at the end of follow-up. At the end of the treatment, cure, as judged by endoscopy, was observed in 74{\%} of fluconazole-treated patients and in 47.2{\%} of itraconazole-treated patients (p <0.01); at the end of follow-up, cure was observed endoscopically in 71.7{\%} of fluconazole-treated patients and in 43.2{\%} of the itraconazole-treated patients (p <0.05). As regards clinical cure, no statistically significant difference was observed between the groups, at the end of pharmacological treatment and at the end of follow-up. The results of this study demonstrate that both fluconazole and itraconazole are efficacious in the treatment of Candida esophagitis in AIDS patients; fluconazole is associated with higher rate of endoscopic cure than is itraconazole.",
author = "Giuseppe Barbaro and Giorgio Barbarini and Lorenzo, {Gabriella Di}",
year = "1995",
doi = "10.3109/00365549509047076",
language = "English",
volume = "27",
pages = "613--617",
journal = "Scandinavian Journal of Infectious Diseases",
issn = "0036-5548",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients

T2 - A double-blind, randomized, controlled clinical study

AU - Barbaro, Giuseppe

AU - Barbarini, Giorgio

AU - Lorenzo, Gabriella Di

PY - 1995

Y1 - 1995

N2 - The aim of this study was to assess the role and the therapeutic efficacy of 2 azole antifungal drugs, fluconazole and itraconazole, in the treatment of endoscopically diagnosed Candida esophagitis in patients with acquired immunodeficiency syndrome (AIDS). The study involved 123 human immunodeficiency virus (HIV)-positive patients (70 males and 53 females, mean age 27 years) at their first episode of esophageal candidiasis diagnosed by endoscopy. The patients were randomized in a double-blind design to receive either fluconazole (100 mb b.i.d. per os) or itraconazole (100mg b.i.d. per os). In order to evaluate the efficacy of treatment, clinical examinations were performed every week up to the end of follow-up (2 months); endoscopic examination was performed at baseline, at the end of treatment (3 weeks) and at the end of follow-up. At the end of the treatment, cure, as judged by endoscopy, was observed in 74% of fluconazole-treated patients and in 47.2% of itraconazole-treated patients (p <0.01); at the end of follow-up, cure was observed endoscopically in 71.7% of fluconazole-treated patients and in 43.2% of the itraconazole-treated patients (p <0.05). As regards clinical cure, no statistically significant difference was observed between the groups, at the end of pharmacological treatment and at the end of follow-up. The results of this study demonstrate that both fluconazole and itraconazole are efficacious in the treatment of Candida esophagitis in AIDS patients; fluconazole is associated with higher rate of endoscopic cure than is itraconazole.

AB - The aim of this study was to assess the role and the therapeutic efficacy of 2 azole antifungal drugs, fluconazole and itraconazole, in the treatment of endoscopically diagnosed Candida esophagitis in patients with acquired immunodeficiency syndrome (AIDS). The study involved 123 human immunodeficiency virus (HIV)-positive patients (70 males and 53 females, mean age 27 years) at their first episode of esophageal candidiasis diagnosed by endoscopy. The patients were randomized in a double-blind design to receive either fluconazole (100 mb b.i.d. per os) or itraconazole (100mg b.i.d. per os). In order to evaluate the efficacy of treatment, clinical examinations were performed every week up to the end of follow-up (2 months); endoscopic examination was performed at baseline, at the end of treatment (3 weeks) and at the end of follow-up. At the end of the treatment, cure, as judged by endoscopy, was observed in 74% of fluconazole-treated patients and in 47.2% of itraconazole-treated patients (p <0.01); at the end of follow-up, cure was observed endoscopically in 71.7% of fluconazole-treated patients and in 43.2% of the itraconazole-treated patients (p <0.05). As regards clinical cure, no statistically significant difference was observed between the groups, at the end of pharmacological treatment and at the end of follow-up. The results of this study demonstrate that both fluconazole and itraconazole are efficacious in the treatment of Candida esophagitis in AIDS patients; fluconazole is associated with higher rate of endoscopic cure than is itraconazole.

UR - http://www.scopus.com/inward/record.url?scp=0029549914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029549914&partnerID=8YFLogxK

U2 - 10.3109/00365549509047076

DO - 10.3109/00365549509047076

M3 - Article

VL - 27

SP - 613

EP - 617

JO - Scandinavian Journal of Infectious Diseases

JF - Scandinavian Journal of Infectious Diseases

SN - 0036-5548

IS - 6

ER -